Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$4.88 ▲ +0.14
(+2.95%)
MKT CAP: $7.3M • VOL: 14.6K
52W L $3 52W H $7
ROARABLE / RQD
D • 48/100
PIOTROSKI
3 / 9
NDRA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$5.8M | -$10.8M | -$10.5M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$7.0M | -$11.5M | -$10.1M |
| EBITDA (Normalized) | -$5.7M | -$10.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$5.2M | -$7.4M | -$9.5M |
| Capital Expenditures (CapEx) | $17.3K | $16.0K | — |
| Free Cash Flow (FCF) | -$5.2M | -$7.4M | -$9.5M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $762.4K | $3.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $2.3M | $2.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NDRA.